文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

血管紧张素Ⅱ治疗与难治性血管扩张性休克ARDS患者氧合改善相关

Angiotensin II treatment is associated with improved oxygenation in ARDS patients with refractory vasodilatory shock.
PubMed 文献 · Ann Intensive Care · 2023-12-16
一句话结论ATHOS-3事后分析:合并难治性血管扩张性休克的ARDS患者,血管紧张素Ⅱ较安慰剂48小时P:F升高98.4 mmHg(95%CI 35.2-161.5)。

该研究为ATHOS-3试验的事后亚组分析,纳入符合改良柏林ARDS标准的81例患者,其中34例(42%)随机接受血管紧张素Ⅱ、47例(58%)接受安慰剂。主要终点为校正基线P:F后48小时的P:F,血管紧张素Ⅱ组由基线155 mmHg(SD 69)升至48小时265 mmHg(SD 160),安慰剂组无变化(148 mmHg(SD 63)至164 mmHg(SD 74)),基线校正差值+98.4 mmHg(95%CI 35.2-161.5),p=0.0028。氧合指数、3小时持续血流动力学应答率亦有改善,PEEP、分钟通气量、通气比值无差异。作者认为这为血管紧张素Ⅱ治疗ARDS合并血管扩张性休克提供了生理学依据。

要点

  • ATHOS-3事后分析纳入81例改良柏林标准ARDS患者,血管紧张素Ⅱ组48小时P:F由155 mmHg升至265 mmHg,安慰剂组148 mmHg至164 mmHg,基线校正差值+98.4 mmHg(95%CI 35.2-161.5),p=0.0028。
  • 氧合指数血管紧张素Ⅱ组48小时下降-6.0 cmH2O/mmHg,安慰剂组-0.4 cmH2O/mmHg,基线校正差值-4.8 cmH2O/mmHg(95%CI -8.6至-1.1),p=0.0273。
  • 3小时持续血流动力学应答血管紧张素Ⅱ组22例(64.7%)vs安慰剂组17例(36.2%),绝对风险差28.5%(95%CI 6.5-47.0%),p=0.0120。
  • PEEP、分钟通气量、通气比值两组无差异;第7天存活且脱机血管紧张素Ⅱ组7/34(20.6%)vs安慰剂组5/47(10.6%),第28天死亡率55.9% vs 68.1%。
  • 作者认为该生理学依据支持开展血管紧张素Ⅱ治疗ARDS合并血管扩张性休克的试验。

适用人群与场景

  • ATHOS-3试验中入组时符合改良柏林ARDS标准、合并儿茶酚胺难治性血管扩张性休克的患者,共81例。

诊断标准与关键阈值

  • 入组时符合改良柏林ARDS标准。

研究设计与关键结果

  • 研究类型:ATHOS-3(Angiotensin Therapy for High Output Shock)试验的事后亚组分析。
  • 81例ARDS患者中34例(42%)随机至血管紧张素Ⅱ、47例(58%)随机至安慰剂。
  • 主要终点48小时P:F:血管紧张素Ⅱ组由基线155 mmHg(SD 69)升至265 mmHg(SD 160),安慰剂组148 mmHg(SD 63)至164 mmHg(SD 74),基线校正差值+98.4 mmHg(95%CI 35.2-161.5),p=0.0028。
  • 氧合指数48小时变化:血管紧张素Ⅱ组-6.0 cmH2O/mmHg vs安慰剂组-0.4 cmH2O/mmHg,基线校正差值-4.8 cmH2O/mmHg(95%CI -8.6至-1.1),p=0.0273。
  • 3小时持续血流动力学应答:血管紧张素Ⅱ组22例(64.7%)vs安慰剂组17例(36.2%),绝对风险差28.5%(95%CI 6.5-47.0%),p=0.0120。
  • 第7天存活且脱机:血管紧张素Ⅱ组7/34(20.6%)vs安慰剂组5/47(10.6%)。
  • 第28天死亡率:血管紧张素Ⅱ组55.9% vs安慰剂组68.1%。
  • PEEP、分钟通气量、通气比值两组无差异。

证据类型、等级与局限

  • 证据类型:随机对照试验的事后亚组分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,这些发现为血管紧张素Ⅱ作为ARDS合并血管扩张性休克治疗的试验提供了生理学依据。

指南或共识出处

  • Angiotensin Therapy for High Output Shock(ATHOS-3)试验,ClinicalTrials.Gov注册号NCT02338843(注册日期2015年1月14日)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The physiological effects of renin-angiotensin system modulation in acute respiratory distress syndrome (ARDS) remain controversial and have not been investigated in randomized trials. We sought to determine whether angiotensin-II treatment is associated with improved oxygenation in shock-associated ARDS.

METHODS: Post-hoc subgroup analysis of the Angiotensin Therapy for High Output Shock (ATHOS-3) trial. We studied patients who met modified Berlin ARDS criteria at enrollment. The primary outcome was PaO2/FiO2-ratio (P:F) at 48-h adjusted for baseline P:F. Secondary outcomes included oxygenation index, ventilatory ratio, PEEP, minute-ventilation, hemodynamic measures, patients alive and ventilator-free by day-7, and mortality.

RESULTS: Of 81 ARDS patients, 34 (42%) and 47 (58%) were randomized to angiotensin-II or placebo, respectively. In angiotensin-II patients, mean P:F increased from 155 mmHg (SD: 69) at baseline to 265 mmHg (SD: 160) at hour-48 compared with no change with placebo (148 mmHg (SD: 63) at baseline versus 164 mmHg (SD: 74) at hour-48)(baseline-adjusted difference: + 98.4 mmHg [95%CI 35.2-161.5], p = 0.0028). Similarly, oxygenation index decreased by - 6.0 cmH2O/mmHg at hour-48 with angiotensin-II versus - 0.4 cmH2O/mmHg with placebo (baseline-adjusted difference: -4.8 cmH2O/mmHg, [95%CI - 8.6 to - 1.1], p = 0.0273). There was no difference in PEEP, minute ventilation, or ventilatory ratio. Twenty-two (64.7%) angiotensin-II patients had sustained hemodynamic response to treatment at hour-3 versus 17 (36.2%) placebo patients (absolute risk-difference: 28.5% [95%CI 6.5-47.0%], p = 0.0120). At day-7, 7/34 (20.6%) angiotensin-II patients were alive and ventilator-free versus 5/47(10.6%) placebo patients. Day-28 mortality was 55.9% in the angiotensin-II group versus 68.1% in the placebo group.

CONCLUSIONS: In post-hoc analysis of the ATHOS-3 trial, angiotensin-II was associated with improved oxygenation versus placebo among patients with ARDS and catecholamine-refractory vasodilatory shock. These findings provide a physiologic rationale for trials of angiotensin-II as treatment for ARDS with vasodilatory shock.

TRIAL REGISTRATION: ClinicalTrials.Gov Identifier: NCT02338843 (Registered January 14th 2015).

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Leisman DE, Handisides DR, Chawla LS, et al. Angiotensin II treatment is associated with improved oxygenation in ARDS patients with refractory vasodilatory shock. Ann Intensive Care. 2023. PMID: 38103056. doi:10.1186/s13613-023-01227-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。